Physician profile
Reza Mohebi
NPI 1891292280
$3,334.83
in general payments reported to CMS, 2019-2025
16 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,781 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,781 · Food and Beverage: $458 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,780.50 |
| Food and Beverage | $457.52 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $2,780.50 | 2023 | Jardiance |
| Novo Nordisk INC | $96.81 | 2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $55.67 | 2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $55.60 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $54.63 | 2025 | Prolia, Evenity |
| Pfizer INC. | $54.52 | 2025 | |
| Glaxosmithkline, LLC. | $38.59 | 2025 | Shingrix, Arexvy |
| Grifols USA, LLC | $33.92 | 2025 | Xembify |
| Ionis Pharmaceuticals, INC. | $33.16 | 2025 | Dawnzera |
| Inspire Medical Systems, INC. | $32.69 | 2025 | Inspire |
| Genentech USA, INC. | $32.58 | 2025 | Xolair |
| Exact Sciences Corporation | $26.56 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $26.14 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.46 | 2025 | Xifaxan |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Mohebi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.